Changchun Hi-tech (000661.SZ): JinSai Pharmaceutical GS3-007a oral suspension domestic drug production registration clinical trial application approved.

Zhitan Finance and Economics APP news, Changchun High-tech (000661.SZ) issued an announcement. Recently, the company's controlling subsidiary - Changchun Jinsai Pharmaceutical Co., Ltd. (hereinafter referred to as "Jinsai Pharmaceutical") received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for the domestically produced drug registration clinical trial application of GS3-007a dry blend suspension. GS3-007a dry blend suspension is an orally administered small molecule growth hormone secretagogue independently developed by Jinsai Pharmaceutical. It is classified as a first-class chemical drug and is intended for the treatment of pediatric growth hormone deficiency-induced growth retardation (PGHD). As of now, there are no similar products on the market in China. The approval of this clinical trial application can promote the subsequent clinical development of this product and meet the unmet clinical needs of patients.